Prothena Corporation plc

NASDAQ:PRTA  
26.80
+0.60 (+2.29%)
Products

Prothena Announces FDA Clearance Of IND For PRX012

Published: 03/28/2022 13:06 GMT
Prothena Corporation plc (PRTA) - Prothena Announces FDA Clearance of Ind for Prx012, a Subcutaneous Anti-amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.
Prothena Corporation Plc - Has Initiated Phase 1 Sad Study of Prx012, Under Investigation for Treatment of Alzheimer's Disease.
Prothena Corporation Plc - Expects to Initiate Phase 1 Multiple Ascending Dose Study by Year-end 2022.